Clinical Trials Browser

INDUSTRY × CUDC-907 × Clear all

NCT01742988 2021-05-06

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Phase 1 Completed

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT02307240 2019-09-03

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Phase 1 Completed

Triple Negative Breast Neoplasms